Uncategorized

Companion Diagnostics Market: Top Players are Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc., (US)

Summary

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region – Global Forecast to 2025 The prominent players operating in […]

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region – Global Forecast to 2025 The prominent players operating in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), Icon Plc (Ireland), and Biogenex Laboratories, Inc. (US).

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=297416

A large-scale Companion Diagnostics Market report sorts out the breakdown of global data by manufacturers, region, type, and application while analyzing the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks, and entry barriers, sales channels, and distributors. For an enhanced user experience of this report, all the facts and figures of statistical and numerical data are represented very well throughout the report. The credible Companion Diagnostics Market report gives estimations about the size of the market with information on key vendor revenues, development of the industry by upstream and downstream, industry progress, key companies, along with market segment type and market application.

“Cancer segment to witness the highest growth during the forecast period”

The cancer segment is estimated to grow at the highest CAGR during the forecast period. This can be attributed primarily to the increasing global incidence of cancer, the growing role of companion diagnostics in personalized medicine treatment for cancer, the rising utility of biomarkers in the diagnosis of cancer, technological advancements in cancer diagnostics at the molecular level, and the availability of funding for cancer research.

“Pharmaceutical & biopharmaceutical companies segment to grow at the highest CAGR in the companion diagnostics market, by end-user”

The major factors driving the demand for pharmaceutical & biopharmaceutical companies in companion diagnostics are growing prominence in drug development and the growing importance of companion diagnostic biomarkers. The increasing demands for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

APAC market to witness the highest growth during the forecast period”

Asia Pacific is estimated to be the fastest-growing regional market for companion diagnostics during the forecast period. The high incidence of cancer, growing proteomics & genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are some of the major factors driving the growth of this market.

The break-down of primary participants is as mentioned below:

  • By Company Type – Tier 1: 40%, Tier 2: 25%, and Tier 3: 35%
  • By Designation – C-level: 33%, Director-level: 41%, and Others: 26%
  • By Region – North America: 38%, Europe: 32%, Asia Pacific: 23%, Latin America: 5%, and the Middle East & Africa: 2%

Research Coverage:

This report analyzes the market for various companion diagnostics and their adoption patterns. It aims at estimating the size and future growth potential of the global companion diagnostics market as well as its segments (by product & service, technology, indication, end-user, and region). The report also includes an in-depth competitive analysis of key market players along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or any combination of the below mentioned five strategies for strengthening their market presence.

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion diagnostics market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service launches in the global companion diagnostics market
  • Market Development: Comprehensive information on the lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion diagnostics market
  • Competitive Assessment: In-depth assessment of product offered, market shares, growth strategies, and revenue analysis of leading players in the global companion diagnostics market

Get Direct Order of this Report @ https://www.reportsnreports.com/purchase.aspx?name=297416

Table Of Contents

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.2.1 Inclusions & Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered For The Study
1.4 Currency
Table 1 Standard Currency Conversion Rates
1.5 Limitations
1.6 Stakeholders
1.7 Summary Of Changes

2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
Figure 2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
Figure 3 Breakdown Of Primary Interviews: By Company Type, Designation, And Region
2.2 Market Size Estimation
Figure 4 Market Size Estimation: Revenue Share Analysis
Figure 5 Revenue Share Analysis Illustration
Figure 6 Market Size Approach
Figure 7 Top-Down Approach
2.3 Market Breakdown And Data Triangulation
Figure 8 Data Triangulation Methodology
2.4 Market Share Analysis
2.5 Assumptions For The Study

3 Executive Summary
Figure 9 Companion Diagnostics Market, By Product & Service, 2020 Vs. 2025 (Usd Billion)
Figure 10 Companion Diagnostics Market, By Technology, 2020 Vs. 2025 (Usd Billion)
Figure 11 Companion Diagnostics Market, By Indication, 2020 Vs. 2025 (Usd Billion)
Figure 12 Companion Diagnostics Market, By End User, 2020 Vs. 2025 (Usd Billion)
Figure 13 Geographical Snapshot Of The Companion Diagnostics Market

4 Premium Insights
4.1 Companion Diagnostics Market Overview
Figure 14 Increasing Demand For Targeted Therapies And Personalized Medicine In The Pharmaceutical Industry To Drive Market Growth
4.2 Asia Pacific: Companion Diagnostics Market, By End User (2019)
Figure 15 Pharmaceutical & Biopharmaceutical Companies Commanded The Largest Share Of The Apac Companion Diagnostics Market In 2019
4.3 Regional Mix: Companion Diagnostics Market
Figure 16 Asia Pacific To Witness The Highest Growth In The Forecast Period
4.4 Companion Diagnostics Market: Developed Vs. Developing Countries
Figure 17 Developing Countries To Register Higher Growth During The Forecast Period
4.5 Geographical Snapshot Of The Companion Diagnostics Market
Figure 18 China To Grow At The Highest Cagr During The Forecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 19 Companion Diagnostics Market: Drivers, Restraints, Opportunities, And Challenges
5.2.1 Drivers
5.2.1.1 Advantages Of Companion Diagnostics
5.2.1.2 Growing Need For Targeted Therapy
5.2.1.3 Growing Importance Of Personalized Medicine
Figure 20 Global Launch Of Personalized Medicine Products, 2008–2016
5.2.1.4 Increasing Global Incidence Of Cancer
Figure 21 Global Cancer Incidence, 2008–2030
5.2.1.5 Growing Application Areas Of Companion Diagnostics
5.2.2 Restraints
5.2.2.1 High Cost Of Companion Diagnostic Tests
5.2.2.2 Uncertain Reimbursement Scenario In Different Regions
Table 2 Companion Diagnostics Reimbursement Scenario Worldwide
5.2.3 Opportunities
5.2.3.1 Increasing Demand For Next-Generation Sequencing
Table 3 Partnerships & Collaborations For Developing Ngs-Based Companion Diagnostic Tests
5.2.3.2 Growing Significance Of Companion Diagnostics In Drug Development
5.2.3.3 Increasing Number Of Clinical Trials
Table 4 List Of Clinical Trials For Companion Diagnostics
5.2.4 Challenges
5.2.4.1 Impact Of The Covid-19 Pandemic
5.2.4.2 Shortage Of Trained Professionals

6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Impact Of The Covid-19 Pandemic On The Companion Diagnostics Market
Figure 22 Impact Of Covid-19 On The Companion Diagnostics Market
6.2.2 Growing Focus On Liquid Biopsy In Companion Diagnostics
6.2.3 Increasing Collaborations
Table 5 Recent Collaborations In The Companion Diagnostics Market
6.3 Regulatory Analysis
6.3.1 North America
6.3.1.1 Us
Table 6 Us: Classification Of Medical Devices
Figure 23 Premarket Notification: 510(K) Approval For Companion Diagnostic Products
6.3.1.2 Canada
6.3.2 Europe
6.3.3 Asia Pacific
6.3.3.1 Australia
6.3.3.2 Japan
Table 7 Japan: Classification Of Medical Devices
6.3.3.3 China
Table 8 China: Time, Cost, And Complexity Of Registration Process
6.3.3.4 India
Figure 24 India: Regulatory Process For Ivd Devices
Table 9 India: Time, Cost, And Complexity Of Registration Process
6.3.4 Brazil
6.4 Product Pipeline Analysis
Table 10 Companion Diagnostics Product Pipeline Analysis, By Market Player: Current Market Scenario

Read More…………….